Exosome Diagnostics Announces Key Appointments To Informatics Group

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc., the developer of a revolutionary liquid biopsy platform that enables non-invasive diagnosis of serious diseases, aiming to reduce or eliminate the need for tissue biopsies, today announced two key appointments to its rapidly growing Informatics group. Vasisht Tadigotla has been appointed as Head of Informatics and Robert Kitchen as Senior Scientist, Informatics.

“We are very pleased to announce that Vasisht Tadigotla and Robert Kitchen have joined our Informatics team at Exosome Diagnostics”

“We are very pleased to announce that Vasisht Tadigotla and Robert Kitchen have joined our Informatics team at Exosome Diagnostics”, said John Healy, VP of Informatics. “As our Informatics group continues to grow, Exosome Diagnostics is building the analytical framework required to enable even deeper insights based on the information-rich, high-dimensional data generated by our novel, non-invasive platform that captures the diverse DNA, RNA and protein markers found in microvesicles. We see this foremost as a communication tool for our companion diagnostic partners, A-to-D collaborators and internal development teams, providing intuitive visualization, rapid feedback and bullet-proof assurance of data quality and best analytical practices. Vasisht and Robert bring the domain expertise and diverse and rare skill sets required to guarantee these capabilities. We are very excited to have them join our team here at Exosome Diagnostics.”

Vasisht Tadigotla brings over 10 years of experience in bioinformatics, genomics, research and technology development. Prior to joining Exosome Diagnostics, Vasisht was a Senior Scientist at Courtagen Life Sciences where he developed automated cloud-based next-generation sequencing (NGS) clinical analysis pipelines in a regulated environment. Before that he was a Staff Scientist at Life Technologies, where he played a key role in developing the Ion Torrent and SOLiD sequencing platforms. He earned his PhD in Biophysics from Rutgers University and a Bachelor’s Degree in Biochemical Engineering from Indian Institute of Technology, Delhi.

Robert R. Kitchen is a senior postdoctoral associate in the laboratories of Mark Gerstein (dept. of Molecular Biophysics and Biochemistry) and Angus Nairn (dept. of Psychiatry) at Yale University. He received his undergraduate degree in astrophysics at the University of Edinburgh in 2007 where he remained to complete an MSc in high-performance distributed computing in 2008 and a PhD in bioinformatics/biostatistics in 2011. His research focus is in the field of computational biology and biostatistics, developing advanced software tools and algorithms for the analysis of high-throughput functional genomic data. He has acquired a wealth of experience and has widely published in a variety of subjects including statistical modeling, data visualization, cellular biology, medical diagnostics, human brain development and heart disease. Robert has been extremely active in the rapidly expanding field of extra-cellular RNA, and the software he created has been adopted as the standard for RNA-seq analysis by the NIH Extracellular RNA Communication Consortium here in the U.S.

“The consistently high quality of the data amassed at Exosome Diagnostics over the past several years, across thousands of samples is very convincing,” said John Boyce, CEO of Exosome Diagnostics. “It is the data we have today, not a vague promise of some future value that is most compelling to our companion diagnostic partners and is currently attracting the top talent in Informatics. It is clear to all this represents the next generation of biomarker discovery and the optimal platform to deliver noninvasive diagnostics.”

About Exosome Diagnostics

Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company’s novel exosome-based technology platform, ExoLutionTM, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. Visit www.exosomedx.com to learn more.

ExoDx is a registered trademark of Exosome Diagnostics, Inc. Exosome Diagnostics and ExoLution are unregistered trademarks of Exosome Diagnostics, Inc.


Feinstein Kean Healthcare
Kelly Donoghue, 617-761-6737
Exosome Diagnostics
Dan Baughman, 248-613-2247

Back to news